Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers.

Cancer therapy-related cardiac dysfunction (CTRCD) is identified as a well-established and potentially life-threatening complication of contemporary oncologic treatment.

• CTRCD can arise across a spectrum of malignancies and cardiovascular presentations.
• The integration of comprehensive cardio-oncology guidelines into routine hematology and oncology practice remains inconsistent.
• The consensus statement was developed by a multidisciplinary panel of cardio-oncology experts to address this implementation gap.

The consensus document applies evidence-based recommendations from both the European Society of Cardiology (ESC) and the International Cardio-Oncology Society (ICOS) guidelines to real-world clinical scenarios.

• The document presents representative clinical scenarios that illustrate real-world challenges in cardio-oncology.
• Guidelines from ESC and ICOS are used as the primary evidence base for the recommendations.
• The framework is described as 'structured' and 'user-friendly' to support informed decision-making by oncology providers.

Baseline cardiovascular risk stratification prior to initiating potentially cardiotoxic therapies is identified as a key focus area, with emphasis on biomarker and imaging surveillance strategies tailored to individual risk profiles.

• Risk stratification is highlighted as essential before starting cardiotoxic cancer treatments.
• Surveillance strategies are described as needing to be tailored to individual patient risk profiles.
• Both biomarker monitoring and imaging are identified as components of appropriate surveillance.

The document outlines the application of guideline-directed medical therapy (GDMT) for cancer patients with heart failure as a core component of CTRCD management.

• GDMT is presented as applicable to cancer patients who develop heart failure as a result of cardiotoxic therapy.
• The framework aims to preserve cancer treatment intensity while minimizing cardiovascular morbidity.
• Early recognition, consistent surveillance, and timely referral to cardiology are emphasized as key management steps.

The consensus statement aims to bridge the implementation gap between oncology and cardiology disciplines by equipping oncology providers with accessible cardio-oncology tools.

• The document is designed specifically to be accessible to hematology and oncology providers rather than cardiologists alone.
• The goal is to facilitate early recognition and consistent surveillance of CTRCD in routine oncology practice.
• Timely referral to cardiology is identified as a key outcome supported by the framework.